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Abstract
Rationale:  Pneumococcal pneumonia remains a global health problem. Colonization of the 
nasopharynx with S.pneumoniae (Spn), although, a prerequisite of infection, is the main 
source of exposure and immunological boosting in children and adults. However, our 
knowledge of how nasal colonization impacts on the lung cells, especially on the predominant 
alveolar macrophage (AM) population, is limited. 
Objectives: Using a Controlled Human Infection model to achieve nasal colonization with 6B 
serotype, we investigated the effect of Spn colonization on lung cells.
Methods: We collected bronchoalveolar lavages from healthy pneumococcal challenged 
participants aged 18-49 years. Confocal microscopy, molecular and classical microbiology 
were used to investigate microaspiration and pneumococcal presence in the lower airways. 
AM opsonophagocytic capacity was assessed by functional assays in vitro, whereas flow 
cytometry and transcriptomic analysis were used to assess further changes on the lung 
cellular populations. 
Measurements and Main Results: AM from Spn-colonized exhibited increased 
opsonophagocytosis to pneumococcus (11.4% median increase) for approximately three 
months after experimental pneumococcal colonization. AM had also increased responses 
against other bacterial pathogens. Pneumococcal DNA detected in the BAL samples of Spn-
colonized were positively correlated with nasal pneumococcal density (r=0.71, p=0.029). 
Similarly, AM heightened opsonophagocytic capacity was correlated with nasopharyngeal 
pneumococcal density (r=0.61, p=0.025). 
Conclusions: Our findings demonstrate that nasal colonization with pneumococcus and 
microaspiration prime AM, leading to brisker responsiveness to both pneumococcus and 
unrelated bacterial pathogens. The relative abundance of AM in the alveolar spaces, alongside 
with their potential for non-specific protection, render them an attractive target for novel 
vaccines. 
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Introduction
Streptococcus pneumoniae (the pneumococcus, Spn) is a leading cause of severe infection, 
responsible annually for the death of up to a million children worldwide (1).  Pneumonia is the 
most frequent manifestation of pneumococcal  disease (2) and despite the current vaccination 
strategies the burden of  pneumococcal pneumonia  remains very high globally (3),  affecting 
disproportionally the very young and very old throughout the world (4). 
Despite its pathogenicity, S. pneumoniae commonly colonizes the human nasopharynx, a 
state known as pneumococcal colonization or carriage (4). Pneumococcal colonization rates 
in the absence of disease range from 40 to 95% in infants and approximately 10-25% among 
adults (5, 6). In humans, exposure to pneumococcus through nasopharyngeal colonization is 
an immunising event, as it elicits humoral and cellular immune-responses, both systemically 
and in the nasal mucosa (7-9). 
However, lung mucosal immune-responses to pneumococcus are not well understood in 
humans. It is believed that protection against development of pneumonia relies on a 
successful regulation of colonization in the nasopharynx and a brisk alveolar macrophage-
mediated immune response in the lung (10). The alveolar macrophage (AM) – an innate type 
resident lung cell- is an integral component of lung immunity (11) and the first cell type to 
combat pneumococci during early infection (12). It also plays a key role in shaping the 
adaptive immunity through their effects on dendritic cells and T cells (13). In murine models, 
it has been shown that AMs are mainly self-maintained, although during lung insult or as a 
result of ageing (14) peripheral monocytes contributes to their replenishment (15, 16).
A clear understanding of the mechanisms that underlie brisk but controlled lung immune-
responses at the early stages of the infection is essential to inform us why high rates of 
pneumonia persists in the high-risk groups (infants, elderly and immunocompromised). These 
high-risk groups are characterized by underdeveloped or defective adaptive immunity. 
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Although, current immunization strategies to pneumococcal diseases target exclusively B cell 
dependent immunity, the recently described memory properties of innate cells, including 
natural killer (NK) cells and monocytes, indicate that innate immune cells could be considered 
as a promising alternative or complementary vaccine target (17-19). 
In this study, we investigated the effect of antecedent pneumococcal colonization on alveolar 
macrophage function in healthy adults. We showed for the first time that nasal human 
colonization in absence of disease leads to pneumococcal aspiration to the lower respiratory 
tract, which enhanced AM opsonophagocytic capacity against a range of bacterial respiratory 
pathogens likely through an interferon-γ (IFN-γ)-mediated mechanism. 
Some of the results of this study have been previously reported in the form of an abstract (20). 
Methods
Study design and bronchoalveolar lavage collection
Healthy, non-smoking, adult volunteers aged from 18-49 years, enrolled in one of the 
Experimental Human Pneumococcal Challenge (EHPC) studies (21) between 2015-2018 (22, 
23) underwent an one-off research bronchoscopy, as previously described (24, 25). 
Experimental human pneumococcal challenge was conducted as previously described (21, 
26) and 80,000 colony-forming-units (CFU) of  serotype 6B (strain BHN418) were instilled into 
each nostril of participants. Pneumococcal colonization was detected by classical 
microbiology methods and individuals were defined as Spn colonized, if any nasal wash 
culture following experimental challenge grew S. pneumoniae serotype 6B. Bronchoalveolar 
lavage samples were obtained from 29 to 203 days post the intranasal inoculation (Figure 1A). 
Spn colonized individuals received 3 doses of amoxicillin at the end of the clinical trial (at day 
14 or 27 or 29) prior to the bronchoscopy (Figure 1A). In addition, a nasopharyngeal swab 
(NPS) was collected in STGG medium (skim milk, tryptone, glucose, and glycerine) on the day 
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of the bronchoscopy and clearance of colonization was assessed by both classical 
microbiology and molecular methods. 
Ethics statement  
All volunteers gave written informed consent and research was conducted in compliance with 
all relevant ethical regulations. Ethical approval was given by the North-West National Health 
Service Research Ethics Committee (REC). Ethics Committee reference numbers: 
15/NW/0146, 14/NW/1460 and 15/NW/0931 and Human Tissue Authority licensing number: 
12548.
Bronchoalveolar lavage processing and alveolar macrophage isolation
Bronchoalveolar lavages (BAL) samples were processed (24, 25) and AMs were routinely 
separated from other cell populations using adherence step, as previously described (27). In 
the experiments that highly pure AM population was requested, AMs were purified from the 
whole BAL sample through cell sorting (FACS ARIAIII), following seeding on 96-well plate and 
overnight incubation at 37oC, 5% CO2 (full details in supplementary methods).
Alveolar macrophage opsonophagocytic assay (OPA)
AMs opsonophagocytic capacity was evaluated as previously described with minor 
modifications (9, 28, 29). Briefly, live Spn serotype 6B or S. pyogenes or S. aureus or E. coli 
were opsonized with human intravenous immunoglobulin (IVIG, Gamunex, Grifols Inc, Spain) 
at 37oC for 15min. An opsonised bacterial strain, baby rabbit complement (Mast Group) and 
isolated AMs were incubated at 37oC for 1hour. Following incubation, 10 µl of reaction mixture 
was plated, in triplicate, onto blood agar (Oxoid) or Luria-broth agar plates and incubated at 
37°C, 5% CO2 overnight. Colony forming units (CFUs) from cell supernatants were counted 
the following day. Multiplicity of infection (MOI) used was 1 :100 for all the gram-positive 
bacteria, except assays where isolated by cell sorting AMs were used. Opsonophagocytic 
killing assay for E. coli was modified as described elsewhere (MOI= 1:20 for 30min) (28). Due 
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to the lack of reading of lysosome acidification within AMs, the term pneumococcal uptake 
than killing was used. (full details in supplementary methods)
Bacterial DNA extraction and quantification of pneumococcal DNA in nasal and lung 
samples
Extraction of bacterial DNA from NPS and BAL samples was performed as previously 
described with minor modifications (30). Presence of pneumococcal DNA in NPS and BAL 
samples was determined using primers and probe specifically designed for 6B serotype, 
targeting on a capsular polysaccharide gene known as wciP, the rhamnosyl transferase gene. 
The primers and probe sequences were: forward primer 5’- 
GCTAGAGATGGTTCCTTCAGTTGAT- 3’; reverse primer 5’- 
CATACTCTAGTGCAAACTTTGCAAAAT- 3’ and probe 5’- [FAM] ACT GTC TCA TGA TAA 
TT [MGBEQ] -3’ as previously published (31) (full details in supplementary methods). 
Confocal microscopy
Fresh BAL cells were washed and stained with anti-human CD14 texas-Red or CD45-
magenta).  Cells were permeabilized and incubated with 6B pneumococcal antisera (Statens 
Serum Institute) for 30 minutes and then with secondary-conjugated antibody (anti-rabbit 488) 
for another 30 minutes. 23F pneumococcal antisera (Statens Serum Institute) was used as 
control antibody. After washing, cells were cytospun onto microscope slides. DAPI solution 
was applied directly on the spun cells for 5 minutes. After washing, samples were mounted 
using Aqua PolyMount (VWR International). Images were captured using an inverted 
TissueFAXS Zeiss Confocal Microscope. Z stacks were recorded at 1μm intervals at either 
40x oil or 63x oil objectives. 
In thawed BAL samples, fixed and permeabilized cells were incubated in blocking solution 
(PBS-5% goat serum), following 1hour incubation with primary antibodies and 45 minutes with 
secondary antibody solution, following rinsing and then mounting with DAPI. Anti-
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pneumococcal capsule anti-6B serum (Statens Serum Institute) was used to stain bacteria, 
whereas macrophages were labelled with anti-human CD169 (Thermoscientific). 
Combinations of Alexafluor conjugated antibodies (Thermoscientific) were used as secondary 
antibodies (488 and 568 with different host specificity). Images were acquired in Olympus 
FV1000 confocal laser scanning microscope using 40x objectives. For the bacterial 
localisation assays, Alexafluor 633-conjugated Wheat germ agglutinin was used prior to 
membrane permeabilization. Z-stack was created from microscope images, elaborated using 
Huygens Essential deconvolution software version 16 (Scientific Volume Imaging, 
Netherlands) and viewed in Imaris 3D reconstruction software 9.4 (Bitplane, Switzerland). 
Flow cytometry assays 
In each flow cytometry assays, the corresponding cell population was stained with 
predetermined optimal concentration of fluorochrome-conjugated monoclonal antibodies 
against human cell surface proteins or intracellular cytokines (full details in supplementary 
methods).
Luminex analysis of Bronchoalveolar lavage fluid 
The acellular BAL fluid was collected post centrifugation of whole BAL sample (400g for 10min 
at 4oC), divided to 1ml aliquots and stored at -80oC until analysis. On the day of the analysis 
samples were concentrated x10 (1ml of BAL supernatant concentrated to 100ul using vacuum 
concentrator RVC2-18), following acquisition using a 30-plex magnetic Luminex cytokine kit 
(ThermoFisher) and analyzed on a LX200 with xPonent3.1 software following manufacturer’s 
instructions. Samples were analysed in duplicates and BAL samples with a CV > 50 % were 
excluded.
AMs gene analysis using Nanostring platform
Nanostring for AM gene analysis was used as previously described (22) (full details in 
supplementary methods).
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Quantification and statistical analysis
Statistical analyses were performed using GraphPad Prism (Version 6, GraphPad Software, 
La Jolla, CA) and R software (version 3.5.1), including Bioconductor packages. P values are 
two-tailed. For parametric groups comparisons, t test was used for unpaired and paired 
groups. For non-parametric groups comparisons, a Mann-Whitney or Wilcoxon test was used 
for unpaired and paired groups, respectively. For gene expression and Luminex analysis p 
values were corrected by applying multiple correction testing (Benjamin-Hochberg). To 
quantify association between groups, Pearson or Spearman correlation test was used for 
parametric or non-parametric groups, respectively. Differences were considered significant at 
p ≤ 0.05 (*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001).
Results
Alveolar macrophages exhibit augmented responsiveness to bacteria for three months 
after experimental pneumococcal colonization. 
We coupled the experimental human pneumococcal challenge model with research 
bronchoscopy to investigate whether and how nasopharyngeal pneumococcal colonization 
affects alveolar macrophage function in healthy adults. BAL sample was collected from both 
pneumococcal (Spn) colonized and non-colonized healthy adults (aged from 18-49yrs) 
between one and seven months (29 to 203 days) post bacterial challenge (Figure 1A). 
Antecedent pneumococcal colonization was associated with 11.4% increase in alveolar 
macrophage capacity to take up pneumococci in vitro, ranged in non-colonized (carriage-) 
from 58.0% to 82.1% (median=69.0%) and in Spn colonized (carriage+) group from 69.1% to 
90.7% (median=80.4%) (p=0.005, Figure 1B). The observed differential AM opsonophagocytic 
activity (OPA) was reproducible between studies and persisted for approximately 2-3 months 
(median= 76 days) following the intranasal pneumococcal inoculation (Figure 1C). Later after 
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challenge (120-203 days), uptake was similar between the two groups, although we were 
insufficiently powered to detect any statistical differences (n=4 per group).  
We also sought to examine whether this enhanced activity was specific to pneumococcus or 
whether AM responses to other pathogens were similarly increased. AMs from Spn colonized 
individuals had greater capacity to take up the respiratory pathogens Streptococcus pyogenes 
and Staphylococcus aureus (increased by 18% and 11%, respectively) when compared with 
AMs isolated from non-colonized individuals (p=0.009 and p=0.038 respectively, Figure 1D). 
For the gram-negative bacterium Escherichia coli there was a non-significant increase in AM 
OPA in the Spn colonized group (median: 20.6% increase, p=0.067, Figure 1D). 
S. pneumoniae can be detected in the lung after clearance of nasal colonization
To investigate whether pneumococcus is the stimulus of the enhanced AM responses in the 
pulmonary mucosa post nasal colonization, we sought to find evidences of presence of the 
pneumococcal challenge strain (Spn6B) in the alveolar spaces. For the detection of 
pneumococcus in the BAL samples, we utilised classical microbiology and/or molecular 
methods targeting a capsular polysaccharide gene specific to Spn6B (wciP). In volunteers 
who underwent bronchoscopy between 29-49 days post challenge, Spn6B DNA was detected 
in the BAL of 41% (9/22) of Spn colonized individuals by qPCR (Table S1), 1 to 3 weeks 
following the clearance of nasal colonization. None of the non-colonized individuals had 
detectable Spn6B DNA in their BAL sample. Additionally, BAL samples collected from 
volunteers between 50-120 days post challenge were negative for presence of Spn6B DNA, 
irrespective of colonization status. Nasal pneumococcal density positively correlated with the 
copies of pneumococcal DNA detected in BAL samples (Figure 2A).  Spn colonized individuals 
differed in both density and duration of the colonization episode (Figure 2B). In addition, AMs 
capacity to take-up pneumococci correlated positively with nasal pneumococcal density 
(Figure 2C).  Also, confocal microscopy was used to qualitatively visualise the location of 
pneumococci in the AM. Pneumococci (Spn6B) were found associated with the surface of 
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AMs or internalised by them, a phenomenon only observed in the Spn colonized group (Figure 
2D-F Video S1). These data suggest that during asymptomatic pneumococcal colonization of 
the nasopharynx, aspiration of pneumococci can occur, modulating the pulmonary 
immunological responses.
CD4+ Th1 skewed responses rapidly prime AMs
To investigate whether the observed augmented AM capacity to take up pneumococci in vitro 
was dependent on lung lymphocytes, we co-incubated AMs with autologous CD3+CD4+ T cells 
during in vitro infection with Spn6B. The presence of CD3+CD4+ T cells enhanced the basal 
AM opsonophagocytic capacity in both non-colonized (1.6-fold, p<0.0001) and Spn colonized 
individuals (1.8-fold, p<0.0001) (Figure 3A). AM opsonophagocytic capacity differed between 
the two groups at baseline (prior to lung-derived autologous CD3+CD4+ T cell addition) and 
remained higher in Spn-colonized when autologous CD4+ T cells were present (Figure 3A). 
To elucidate the mechanism underlying this increased boosting of AM function by CD4+ T cells 
from Spn colonized individuals, we stained lung lymphocytes intracellularly for T-box 
transcription factor expressed in T-cells (T-bet), GATA-binding protein-3 (GATA-3) and 
Forkhead box P3 (FoxP3) transcription factors (Figure S1). In the Spn colonized group the 
levels of CD4+ T-bet expressing cells were twice as high than in the non-colonized group (p= 
0.003), indicating Th1-polarisation (Figure 3B). There were no significant differences in the 
levels of neither CD4+ GATA-3 expressing nor CD4+ FoxP3 expressing T cells between the 
two groups (Figure 3B). 
In parallel, lymphocytes from both Spn colonized and non-colonized volunteers were 
stimulated with pneumococcal antigen (Heat Inactivated-Spn6B).  Cytokine (IFN-γ, Tumour 
necrosis factor a [TNF-α] or Interleukin 17A [IL-17A]) producing CD4+ T-cells were 
subsequently detected by flow cytometry (Figure S2). AM OPA correlated with cytokine 
producing CD4+ T cells, classified as spontaneous (unstimulated) or pneumococcal-
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responding cells (Figure 4). Increased levels of IFN-γ producing CD4+ T cells, both 
pneumococcal-specific and spontaneous responding, positively correlated with AM ability to 
take up live pneumococci in vitro. (Figure 4A). On the other hand, AM OPA correlated 
positively with only the pneumococcal-specific TNF-α producing CD4+ T cells (Figure 4B), 
whereas IL-17A producing CD4+ T cells did not correlate with AM OPA in any condition (Figure 
4C). 
Together, these results indicate that skewing of CD4+ T cells and production of IFN-γ 
associated with the increased capacity of AM to take up bacteria.
Alterations of lung cytokine milieu post nasal colonization and the effect of IFN-γ on 
AM opsonophagocytic capacity
The alveolar microenvironment is crucial for cell signalling, shaping how local cells respond to 
different stimuli (32).  To assess alterations of the alveolar cytokine milieu induced by nasal 
pneumococcal colonization, we measured levels of 30 cytokines in the BAL fluid retrieved from 
both Spn colonized and non-colonized individuals (Figure 5A, Table S2). Levels of GM-CSF 
(median 0.96 pg/mL vs 0.49 pg/mL), IFN-γ (median 3.92 pg/mL vs 1.88 pg/mL) and IFN-α 
(median 2.96 pg/mL vs 3.61 ng/mL) were higher in the BAL fluid of Spn colonised than non-
colonised group, although statistical significance was lost upon correcting for multiple testing 
(Fig 5B and Table S2). As our results on lung derived CD4+ T cells polarization profile in Spn 
colonised, together with the strong correlation between AM opsonophagocytic capacity and 
levels of IFN-γ producing CD4+ T cells were point out towards IFN-γ, we sought to address 
its effect on AM function. Directly before the OPA, AMs were stimulated with exogenous IFN-
γ, either with a concentration that would reflect better the average in vivo levels of IFN-γ in the 
lung lining fluid of Spn colonized group (0.4ng/ml) or with 2ng/ml. Sole addition of IFN-γ 
enhanced significantly the AM capacity to take up pneumococci in both concentrations 
(median: 1.37-fold change using 0.4ng/ml and 1.45-fold change using 2ng/ml of recombinant 
IFN-γ) (Figure 5C). We also investigated further the role of IFN-γ upon AM activation by 
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stimulated them with 10-fold increasing concentrations of exogenous IFN-γ. The lowest tested 
titers of IFN-γ (2 and 20ng/ml) augmented AMs OPA, resulting both in 1.5-fold increase (1.5x 
median; IQR:1.2x- 2.1x) in AM pneumococcal uptake, whereas no significant increase was 
seen with the highest used concentrations (200 and 2000ng/ml) (Figure 5D). These results 
were verified when AM response was assessed using a flow cytometric cytokine production 
assay (Figure S3). AMs produced increased levels of TNF-α in response to stimulation with 
HI-Spn6B only at the lower pre-stimulation doses of IFN-γ (Figure 5E). The mechanism seems 
to have a threshold, as demonstrated by the data, with IFN-γ signalling being beneficial for 
AM function at lower doses in vitro, but not at higher concentration. 
Pneumococcal colonization may promote monocyte-to-macrophage differentiation in 
the alveolar spaces
Previously, we have demonstrated that AM phenotype is not altered by nasopharyngeal 
pneumococcal colonization, as defined by classical monocyte polarisation surface markers 
(24). However, given the increased capacity of AM to take up pneumococci, we extended our 
assessment to other lung myeloid cell populations and neutrophils, in order to determine 
whether recent pneumococcal carriage alters the distribution of these cells in the airway 
(Figure S4). Spn colonized individuals displayed significantly greater AM levels (1.2-fold 
increase, p=0.04) and higher AM/monocyte ratio (2.3-fold increase, p=0.04) in the lung 
compared to non-colonized individuals (Figure 6A). On the other hand, monocyte levels, both 
total and CD14hiCD16lo and CD14hiCD16hi subsets, had no significant difference between the 
two groups, despite their trend for increased presence in the non-colonized group (Figure 6A-
B). Similarly, no difference in neutrophil levels was observed between the two groups (Figure 
6B), indicating that nasal carriage in absence of disease does not lead to neutrophil 
recruitment to the lung.
To test whether antecedent pneumococcal colonization led to monocyte differentiation and 
AM activation, we sought to identify the differential gene signatures of Spn colonized and non-
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colonized volunteers. We isolated AMs by cell sorting from a subset of BAL samples and 
performed NanoString expression analysis of 594 immunological genes. Gene set enrichment 
analysis was performed on all genes, ranked from high to low expressed in the Spn colonized 
compared to the non-colonized group, using published blood transcriptional modules (Table 
S3) (33). Purified alveolar macrophages from Spn colonized individuals showed an 
enrichment in pathways of cell differentiation and function, revealing under-presentation of 
monocytes surface markers and over-presentation of antigen-presentation markers in the Spn 
colonized group (Figure 6C). Some of the genes in these sets that were most increased or 
decreased in Spn colonized individuals included: HLA-DQA1, CLEC7A, LY96 and HLA-DPB1 
(antigen presentation module M5.0) and PTAFR, FCGRT and CD4 (monocyte surface 
signature-module S4). This finding complements the previous observation that nasal Spn 
colonization may lead to monocyte-alveolar macrophage differentiation. We then looked 
whether individual AM gene expression was associated with colonization and/or function. 
Between, the two groups 34 genes were altered, although none remained significant after 
correction for multiple testing (potentially due to small sample size of 5 per group) (Table S4). 
Moreover, when the AM OPA per individual was compared with gene expression (log counts 
per million [CPM]) measured for each of the 594 genes, 34 genes were positively correlated 
with AM function to take up the bacteria (Table S5). Four genes were both positively correlated 
with AM OPA and increased in Spn colonized individuals: T-box 21 (TBX21), ecto-5'-
nucleotidase (NT5E), Carcinoembryonic antigen-related cell adhesion molecule 6 
(CEACAM6) and Toll like receptor 8 (TLR8) (Figure 6D).
Discussion
This study provides insights into the immune responses elicited at the human pulmonary 
mucosa post a pneumococcal carriage episode. Using our experimental human 
pneumococcal challenge model, we demonstrated that prior nasopharyngeal pneumococcal 
colonization results in bacterial aspiration to the lower airspaces, leading to a brisker AM 
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opsonophagocytic capacity against both pneumococcus and other bacterial pathogens. 
Aspirated pneumococci most likely act as the stimulus that leads to enhanced AM 
responsiveness mediated by AM - CD4+ T cells cross-talk and Th1 cytokine secretion. 
Systemic effects of colonization may have also contributed to the heightened lung immune 
responses. However, the systemic profile of immune cells usually does not reflect the mucosal 
sites, due to compartmentalization (39). Also, in the past we described that the effect of 
pneumococcal colonization on cognate T cells is more pronounced in the lung than in blood 
(9).  Despite temporary influences from blood, the human lung exhibits a unique 
microenvironment that adapts to environmental challenges, and so do AM adapt to 
accommodate the ever-changing needs of the tissue (33).
The lung mucosa is not the sterile environment previously thought (34, 35). By employing 
classical microbiology, molecular and visualization methods, we demonstrated that 
pneumococcal aspiration occurs during nasal pneumococcal colonization, a phenomenon that 
was previously observed only in pneumonia cases (36, 37).  The positive correlation between 
AM opsonophagocytic activity and nasal pneumococcal density suggested pneumococcal cell 
trafficking from the nasopharynx to the lung airways. Spn-colonized volunteers received 
amoxicillin treatment prior the bronchoscopy to clear pneumococcal colonization. This was a 
pre-requisite in sampling the human lung without artificially introducing pneumococci, however 
it is possible that bacterial fragments generated during the antibiotic treatment might trigger 
host responses both systemically and at the respiratory mucosal sites. Although, it is difficult 
to assess the direct effect of this intervention on the AM responsiveness, our findings indicate 
that AM function is equally increased in those Spn-colonized volunteers who had naturally 
cleared colonization 1 to 2 weeks prior the antibiotic treatment. 
Interestingly, pneumococci were detected inside AMs or isolated alive from the BAL sample 
of Spn colonized individuals when colonization had cleared a few days prior to the 
bronchoscopy. This observation merits of deeper investigation in the aspects of pneumococcal 
Page 15 of 51  AJRCCM Articles in Press. Published on 18-October-2019 as 10.1164/rccm.201903-0607OC 
 Copyright © 2019 by the American Thoracic Society 
16
survival inside AMs, analytical characterisation of the AM subsets in the health human lung 
and molecular signatures that drives differential AM function. Linked to the recent finding that 
pneumococcus has the ability to survive and replicate within murine splenic macrophages 
(56), there is an urgent need to analyse human AM to single cell levels. AM subpopulations 
that retain pneumococci or internalize them utilizing receptors that could lead to insufficient 
bacterial lysis could stand as potential pneumococcal reservoir. 
In addition, the increased opsonophagocytic capacity displayed by AM post colonization was 
a non-specific response to pneumococcal stimulus. AM responded with equal efficacy to both 
Spn and other gram-positive respiratory pathogens in vitro.  By contrast, we did not see 
significant enhancement of AM opsonophagocytic activity (OPA) against E. coli, although the 
small sample size used might have limited the detection of a less pronounced difference 
between the two experimental groups. 
Our observation shares some similarities with the findings of emerging studies on “trained 
immunity” (or innate immune memory) (19, 38), which reported increased responsiveness of 
innate immune cells to microbial stimuli, caused by epigenetic changes, post their activation 
by varying stimuli (e.g. Bacille Calmette-Guerin [BCG] or measles vaccination). Similarly to 
our observation, this augmented functional state persisted for weeks to months, and 
additionally conferred resistance to reinfection or heterologous infection (17, 18, 39, 40). 
Further controlled human infection studies, including pre- and post- pneumococcal challenge 
BAL sampling and focusing on AM epigenetic and metabolic changes, will be able to address 
whether human alveolar macrophages acquire a “trained immunity” phenotype as response 
to pneumococcal exposure. It will also enable comparisons of immune-responses pre- and 
post- colonization on individual level. 
Our findings on CD4+ Th1 skewed responses and exogenous IFN-γ effect on AM antimicrobial 
function supported the idea that Th1 type responses and interferons are crucial in controlling 
bacteria at the early stages of infection. Increased rates of pneumococcal colonization in 
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children and clinical cases of pneumonia in adults have been associated with a reduction in 
systemic circulating Th-1 (IFN-γ secreting) CD4+ T-cells (41, 42). Polymorphisms in the 
adaptor MAL, which regulates IFN-γ signalling (43), have been associated with altered 
susceptibility to a number of infectious diseases including severe pneumococcal disease(44). 
Moreover, we observed a rapid priming of AMs when co-cultured with autologous lung derived 
CD4+ T cells in vitro. A very recent study in mice described a similar mechanistic link between 
adaptive and innate immune system, suggesting that effector CD8+ T cells, in the context of 
respiratory adenoviral infection, are able to prime AM and render innate memory via IFN-γ(45). 
Our study highlighted that IFN-γ has a dose-dependent effect on human AM function, which 
offers an explanation to the contradictory reports around this topic. For instance, in murine 
models high production of IFN-γ during influenza infection impaired phagocytosis and killing 
of S. pneumoniae by alveolar macrophages (46, 47). In contrast, many other evidences 
suggest that induction of IFN-γ secretion, related to non-acute viral infection, is beneficial for 
innate immune cells, promoting a range of antimicrobial functions, plus macrophage 
polarization and activation (45, 48, 49). The dose-dependent effect of IFN-γ on AM OPA could 
also explain why HIV-infected adults are still at increased risk of developing pneumococcal 
pneumonia, despite the preserved Th1 responses against S. pneumoniae (50). 
By assessing AM gene expression levels, we found that AM population derived from Spn 
colonized individuals was characterized by increased antigen-presentation and decreased 
monocytes surface markers signature. Our flow-based data corroborated this result by 
showing greater AM levels and increased AM to monocyte ratio in the Spn colonized 
individuals. The positive correlation of AM OPA with genes such as  NT5E (or CD73) (51) and 
TBX21 (a master regulator of Th1 responses) indicate at some degree that monocyte-to-
macrophage differentiation and AM polarisation to a more active functional state occur in the 
human lung, after interacting with the pneumococcus. Studies on human 
monocytes/macrophages have reported detectable expression of CD73 in only M(LPS-TNF) 
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polarized cells and increased of T-bet mRNA displayed by M1 polarized macrophages (52, 
53). Also, our finding on increased expression of TLR8 in the Spn colonized group might be 
the readout of IFN-γ signalling, as TLR8 is responsive to interferons. Increase in TLR8 levels 
might lead to enhanced viral sensing and thus have a beneficial effect upon viral infection, 
such as influenza. 
In conclusion, this study emphasizes the effect that nasopharyngeal pneumococcal 
colonization has upon the pulmonary innate immune system, describing the potential 
pathways for the development of a robust immune response. It is well accepted that 
colonisation is a prerequisite for disease. However, disease is more likely caused immediately 
after acquisition of colonization (54, 55). During longer colonization episodes, AMs display the 
increased functionality we described, which in turn could lead to reduced risk of bacterial 
respiratory infections. It is also important to note that our findings derive from young healthy 
adults, which are not at high risk of pneumococcal disease. The elderly are at an increased 
risk of infection and these are colonised less frequently. The lack of repeated colonization and 
associated AM (and other immunological) boosting could contribute to their increased 
susceptibility and explain the paradox of low colonisation and high disease in the elderly.
The seeding of human lung with activated AM that exert prolonged and enhanced 
opsonophagocytic properties has potential implications for vaccine development. 
Pneumococcal vaccines that focus solely on inducing a robust Th17 response may not be the 
best strategy for vaccine targeting serotype-independent protection against pneumonia. On 
the other hand, such a non-specific boosting of innate lung immunity may be an alternative 
strategy to successful pneumonia prevention, especially for the new-borns, whose immune 
system is still developing, or for the elderly, whose acquired immunity is beginning to wear off.  
In particular the elderly, who have been described as an age group with high incidence of 
community-acquired pneumonia cases, would benefit from the boosting effect that mucosal 
stimulation with whole cell pneumococcus confers to the lung immune cells. These results, in 
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combination with our previous finding on increased frequency of pneumococcal-specific CD4+ 
Th-17 cell in human lung post nasal colonization (27), suggest that a nasally administered live-
attenuated pneumococcal vaccine could augment the pulmonary immune-responses and 
confer serotype-independent protection against development of pneumococcal pneumonia. 
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Figures
Figure 1: AMs display an increased opsonophagocytic activity (OPA) against bacterial 
pathogens for a prolonged period post nasal pneumococcal carriage.  A) Defined time-
period of BAL samples collection from Spn colonized (carriage+) and non-colonized (carriage-
) individuals within three independent Experimental Human Pneumococcal Challenge (EHPC) 
studies. Individuals were purposively sampled according to colonization state. After the final 
nasal wash (day 27, 17 or 29 based on study), Spn colonized individuals received a three-day 
course of antibiotics. B) Percentage of pneumococcal uptake by AM post in vitro infection in 
carriage- (n=35) and carriage+ (n=37) group. **p=0.005 by Mann-Whitney test. Multiplicity of 
infection (MOI) used was 1: 100. C) Chronological representation of all BAL samples (n=72) 
collected from one to six months post intranasal pneumococcal inoculation divided into three 
consecutive time periods. T1: p= 0.001, T2: p= 0.003 and T3: p= 0.82 by Mann-Whitney test. 
D) Percentage of bacterial uptake by AM post in vitro infection with Spn6B or S. aureus or S. 
pyogenes or E. coli. **p= 0.009, **p= 0.009, *p= 0.038 and p=0.067, respectively by Mann-
Whitney test. Boxplots and individual subjects are depicted with Carriage- in black dots and 
Carriage+ in red dots. 
Figure 2: Evidence of pneumococcal presence in the lung of nasopharyngeal Spn 
colonized individuals. A) Positive correlation between the nasal pneumococcal density, 
expressed as the Area Under the Curve (log AUC) and the copies of pneumococcal DNA 
(Spn6B) detected in the BAL fluid of carriage+ individuals. r= 0.71, *p=0.029 by Pearson 
correlation test. B) Duration and density of nasal colonization per individual with detected 
Spn6B DNA in the BAL fluid (9 in 22 Spn colonized). The end of each coloured line indicates 
the time point that the individual cleared colonization, assessed by classical microbiology. C) 
Positive correlation between the nasal pneumococcal density (log AUC) and sorted AMs 
opsonophagocytic activity (n=13). Pearson correlation test results and linear regression line 
with 95% confidence interval are shown. D-F) Representative images taken by confocal 
microscope showing: D) pneumococci around AMs and E) internalised pneumococci by AMs 
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derived from Spn colonized individuals. CD5-magenta, CD14-red, nucleus-blue (DAPI) and 
Spn6 capsule-green. Scale bar= 2μm. Inset panels represent Z-stack images of the cell with 
internalised pneumococcus.  F) 3D reconstruction of deconvolved Z-stack confocal images of 
alveolar macrophages. The samples were stained with either wheat germ agglutinin (on the 
left; magenta) or anti-CD169 monoclonal antibody (on the right; red). Spn6 in green and nuclei 
in blue (DAPI).  Video images of the 3D reconstructions are available as a supplementary file. 
A scale bar is shown on the images. 
Figure 3: AM cross-talk and priming by autologous CD4+ T subsets.  A) Comparison of 
phagocytic activity between sorted AM and sorted AM plus autologous BAL isolated CD4+ T 
cells from both carriage- (n=11) and carriage+ (n= 13). MOI=1:20. AM and CD4+ T cells were 
used in a 10:1 ratio. ****p< 0.0001 in both groups by paired t-test. Comparison of AM basal 
opsonophagocytic activity between the two groups. *p= 0.018 by unpaired t-test with Welch’s 
correction. Comparison of AM opsonophagocytic activity in the presence of lung CD4+ T cells 
between carriage- and carriage+ group. **p= 0.001 by unpaired t-test with Welch’s corrections. 
Boxplots and individual subjects are depicted with carriage- in black carriage+ in red, with 
paired samples connected by dashed line. B) Intracellular staining of CD4+ T cells for T-bet, 
GATA-3 and FoxP3 transcription factors, expressed as percentage of CD3+CD4+ BAL 
lymphocytes. **p= 0.003, p= 0.85, p= 0.33 respectively by unpaired t-test with Welch 
correction test. Boxplots and individual subjects are depicted with carriage- in black dots and 
carriage+ in red dots.
Figure 4: Correlations of AM opsonophagocytic activity with CD4+ Th1 and Th17 
responses.  A) From left to right are illustrated significant correlations between the levels of 
IFN-γ expressing CD4+ T cells at baseline (non-stimulated), total IFN-γ expressing CD4+ T 
cells post stimulation with Heat Inactivated (HI) Spn6B and the Spn-specific responding CD4+ 
T cells (non-stimulated condition subtracted from Spn-stimulated condition) with alveolar 
macrophage capacity to take up pneumococci. Spearman Rho and p values are shown. B) 
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Significant correlation of Spn-specific, TNF-α expressing CD4+ T cells with AM OPA. 
Spearman Rho and p value are shown. C)  From left to right are illustrated the levels of IL-
17A expressing CD4+ T cells at baseline and the levels of total and Spn-specific, IL-17A 
expressing CD4+ T cells in association with AM OPA. No significant correlations. Spearman 
correlation test results and linear regression line with 95% confidence interval (purple 
shedding) interval and are shown. 
Figure 5: Lung cytokine milieu, alterations post nasal colonization and the effect of IFN-
γ on AM opsonophagocytic function. A) Heatmap of the 30 cytokines levels, expressed as 
log10 median (pg/mL), measured in the BAL fluid (carriage-; n=20 and carriage+; n=22). B) 
Levels of different cytokines between the two groups, expressed as pg/ml. GM-CSF, IFN-γ 
and IFN-a with *p= 0.032, *p=0.047 and *p=0.043 respectively analysed by Mann-Whitney 
test. Statistical significance was lost upon correcting for multiple testing. Boxplots and 
individual subjects are depicted with carriage- in black dots and carriage+ in red dots.  C) 
Treatment of AMs with 0.4ng/ml (average IFN-γ contraction measured in the BAL fluid of 
carriage+) and 2ng/ml of exogenous IFN-γ. D) The effect of 10-fold increasing doses of 
exogenous IFN-γ (2-2000ng/ml) on the capacity of AM to take up pneumococcus (live Spn6B 
used, MOI= 1:100). AM isolated from 6 non-challenged subjects. Individuals samples are 
depicted and connected by dashed lines.  P values by Friedman test followed by Dunn’s 
multiple comparison are shown. E) TNF-a production from AMs, pre-treated or not with 
exogenous IFN-γ (2-2000ng/ml), following stimulation with HI-Spn6B. AM isolated from 4 non-
challenged subjects. Individuals samples are depicted and connected by dashed lines. P 
values by Friedman test followed by Dunn’s multiple comparison are shown.
Figure 6: Pneumococcal colonization may promote monocyte-to-macrophage 
differentiation. A) Levels of monocytes and AMs in the BAL of carriage- (n=8) and carriage+ 
(n=9), expressed as percentage of CD45+ cells. Significant comparison of AM levels and AM: 
Monocytes ratio between the two study groups, *p=0.046 by Mann-Whitney test. Boxplots and 
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individual subjects are depicted with carriage- in black and carriage+ in red. B) Monocytes 
and neutrophils analysed based on their CD14, CD16 expression.  In monocytes, CD16 
expressional levels divided them to two subsets, CD14hiCD16lo and CD14hiCD16hi. Boxplots 
and individual subjects are depicted with carriage- in black and carriage+ in red. C) Top 
pathways after gene set enrichment analysis for pathways and function applied on 2logFC (n= 
5 subjects per group). Leading edge of genes per pathway is shown. NES presented in 
gradient colour. Red shades indicate pathways over-presented, whereas with blue is depicted 
the pathway under-presented in the carriage positive group. p values as shown on the graph. 
D) Correlations between alveolar macrophage OPA and 2log CPM of TBX21, NT5E, TLR8 
and CEACAM6. Spearman correlation test results and linear regression line with 95% 
confidence interval (purple shedding) interval and are shown.
Page 27 of 51  AJRCCM Articles in Press. Published on 18-October-2019 as 10.1164/rccm.201903-0607OC 
 Copyright © 2019 by the American Thoracic Society 
Figure￿1
A
B C
D
Page 28 of 51 AJRCCM Articles in Press. Published on 18-October-2019 as 10.1164/rccm.201903-0607OC 
 Copyright © 2019 by the American Thoracic Society 
Figure 2
D E
F
A B
C
Page 29 of 51  AJRCCM Articles in Press. Published on 18-October-2019 as 10.1164/rccm.201903-0607OC 
 Copyright © 2019 by the American Thoracic Society 
Figure 3
A
B
Page 30 of 51 AJRCCM Articles in Press. Published on 18-October-2019 as 10.1164/rccm.201903-0607OC 
 Copyright © 2019 by the American Thoracic Society 
Figure￿4
A
B
C
Page 31 of 51  AJRCCM Articles in Press. Published on 18-October-2019 as 10.1164/rccm.201903-0607OC 
 Copyright © 2019 by the American Thoracic Society 
Figure￿5
A B
C D
E
Page 32 of 51 AJRCCM Articles in Press. Published on 18-October-2019 as 10.1164/rccm.201903-0607OC 
 Copyright © 2019 by the American Thoracic Society 
Figure 6
A B
C
D
Page 33 of 51  AJRCCM Articles in Press. Published on 18-October-2019 as 10.1164/rccm.201903-0607OC 
 Copyright © 2019 by the American Thoracic Society 
Online Data Supplement
Material and Methods
Experimental human pneumococcal challenge (EHPC)
Experimental human pneumococcal challenge was conducted in Liverpool as previously 
described (1, 2). Briefly, mid-log-growth vegitone culture of Streptococcus pneumoniae 
serotype 6B (strain BHN418) was prepared and stored at -80oC, and independently tested by 
Public Health England for purity and antibiotic sensitivity. 80,000 colony-forming-units (CFU) 
were instilled into each nostril of participants. Pneumococcal colonization was detected by 
classical microbiology methods and individuals were defined as Spn colonised (carriage+) if 
any nasal wash culture following experimental challenge grew S. pneumoniae serotype 6B.
Bronchoalveolar lavage processing
Bronchoalveolar lavages (BAL) samples were processed as previously described (3, 4).  
Briefly, the BAL fluid was filtered using sterile gauze and centrifuged at 400g for 10 min at 
4°C. The supernatant was removed, the cell pellet was resuspended and washed with PBS. 
The centrifugation step was repeated once, and the cell pellet was resuspended in cold RPMI 
medium (Gibco™ RPMI 1640 Medium) containing antibiotics (Penicillin, Neomycin and 
Streptomycin, Sigma-Aldrich, Sigma Chemical Co) (hereafter referred to as complete RPMI). 
Cell counts in each BAL sample were performed using a haemocytometer.
Alveolar macrophages isolation 
AMs were routinely separated from other cell populations by seeding and adherence on 24-
well plate (Greiner Bio-One, Kremsmünster, Austria), as previously described (5). After 4h 
adherence step, the non-adherent fraction was removed, and the AMs were washed with 
complete RPMI, following overnight incubation at 37oC with 5% CO2. In the experiments that 
highly pure AM population was requested, AMs were purified from the whole BAL sample 
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through cell sorting (FACS ARIAIII), following seeding on 96-well plate and overnight 
incubation at 37oC, 5% CO2. 
Alveolar macrophage opsonophagocytic assay (OPA)
AMs opsonophagocytic capacity was evaluated as previously described with minor 
modifications (5). Briefly, live S. pneumoniae serotype  6B  (inoculation strain) or S. pyogenes 
or S. aureus or E. coli  were opsonized in a 1∶16 final dilution of human intravenous 
immunoglobulin (IVIG, Gamunex, Grifols Inc, Spain) in HBSS +/+ (with Ca2+ Mg2+) at 37oC 
for 15min. AMs were washed twice with RPMI without antibiotics, and incubated with an 
opsonised bacterial strain in Opsonisation Buffer B (HBSS +/+ plus 1% gelatine solution and 
5% FBS)  and baby rabbit complement (Mast Group) at 37oC on a shaking rotor for 60min. 
Following incubation, 10 µl of reaction mixture was plated, in triplicate, onto blood agar (Oxoid) 
or Luria-broth agar plates and incubated at 37°C, 5% CO2 overnight. Colony forming units 
(CFUs) from cell supernatants were counted the following day. Multiplicity of infection (MOI) 
used was 1 :100  for all the gram-positive bacteria. Opsonophagocytic killing assay for the 
gram-negative (E. coli) was modified as described elsewhere (MOI= 1:20 for 30min) (6). In the 
assays where isolated by cell sorting AMs were infected with opsonised Spn6B, the MOI was 
modified to 1:20 due to increased loss of cells during the high-throughput cell sorting. In some 
experiments AMs were stimulated with 0.4ng/ml, 2ng/ml, 20ng/ml, 200ng/ml and 2,000ng/ml 
of recombinant IFN-γ (Bio-techne). 
Bacterial DNA extraction and quantification of pneumococcal DNA in nasal and lung 
samples
Extraction of bacterial DNA from both nasopharyngeal swabs (NPS) and BAL samples was 
performed as previously described with minor modifications (7). Briefly, 300ul of STGG for NP 
swabs or 30mls of BAL sample was centrifuged at max speed for 15min. Following 
centrifugation, the supernatant was discarded, and DNA was extracted from the pellet using 
the Agowa kit for bacterial DNA extraction. The extracted DNA was eluted in a volume of 63ul 
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of elution buffer. DNA purity and quality were assessed by a spectrophotometer (Nanodrop 
ND-1000, Thermo Fisher Scientific). 
Presence of pneumococcal DNA in BAL samples was determined using primers and probe 
specifically designed for 6B serotype, targeting on a capsular polysaccharide gene known as 
wciP, the rhamnosyl transferase gene. The primers and probe sequences were: forward 
primer 5’- GCTAGAGATGGTTCCTTCAGTTGAT- 3’; reverse primer 5’- 
CATACTCTAGTGCAAACTTTGCAAAAT- 3’ and probe 5’- [FAM] ACT GTC TCA TGA TAA 
TT [MGBEQ] -3’ as previously published (8). Primers and probe used in their optimised 
concentrations, 900nM primers and 200nM TaqMan MGB probe per reaction. A non-template 
control and a negative control per DNA extraction, were included in every run. DNA was 
amplified with the real-time PCR System (Agilent Technologies, Statagene Mx3005P) by using 
the following cycling parameters: 95oC for 10 min, followed by 40 cycles at 95oC for 15 sec 
and 60oC for 1 min. A standard curve of a 10-fold dilution series of genomic DNA extracted 
from Spn6B was used. The genomic DNA was extracted using the Qiagen Genomic-tip 20/G 
Kit (Qiagen) and quantified by nanodrop.   The conversion from weight pneumococcal DNA to 
number of DNA copies S. pneumoniae was based on the weight of one genome copy TIGR4 
calculated by the genome length in base pairs times the weight of a DNA base pair (650 
Dalton). The lower limit of detection (LLOD) of the method was set at 40 cycles. Amplification 
values > 40. A sample was considered positive if at least two of three yielded a positive result 
within the < 40-cycle cut-off. Data was analysing using MxPro software.
Flow cytometry assays 
AM and monocyte immunophenotyping: Myeloid lineage cells were immunophenotyped using 
monoclonal antibodies for key surface markers. In brief, whole BAL cells (1 x 106 cells) were 
stained with Aqua Viability dye (LIVE/DEAD® Fixable Dead Cell Stain kit, Invitrogen, UK), 
anti-CD45 FITC, anti-CD80 APC-H7, anti-CD86 PE, anti-CD206 PE-CF594, anti-CD14 PerCP 
Cy5.5, anti-CD16 PE Cy7, anti-CD163 APC, anti-CD11b AF700, anti-CD11C PB, anti-CD64 
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BV605 and anti-HLADR BV785. All the samples were acquired on a FACS ARIA III 
sorter/cytometer (BD Biosciences) and analyzed using Flowjo version 10 (Treestar). BAL 
samples with macroscopically visual red blood cell contamination were excluded from the 
analysis.
AM stimulation with HI-Spn6B and IFN-γ: 1 million of BAL cells per condition, resuspended in 
complete RPMI, were added in 24-well plate and incubated overnight at 37oC, 5% CO2. Non-
adherent cells were removed, and AMs were washed 3x with pre-warmed plain RPMI, 
following stimulation with 10x increased concentration of IFN-γ (2ng/ml, 20ng/ml, 200ng/ml 
and 2,000ng/ml) for 30min. Post the cytokines stimulation, cells received 5μg/ml of heat-
inactivated (HI) Spn6B and were incubated for 2 hours. Non-cytokine/non-Spn treated and 
non-cytokine/Spn treated controls were included per volunteer. Cytokines were retained within 
the cells by the addition of GolgiPlug (BD Biosciences) and stimulation for 2 more hours. Post 
incubation time, AMs were washed with PBS and detached from the wells by adding of 2.5mM 
EDTA solution. Cells were collected in FACS tubes and pelleted (400g for 10 min 
centrifugation), following staining for human AM surface markers - anti-CD14 PerCyP5.5, anti-
CD169-PE, CD206 PE-CF594 and CD45 Pacific Orange and anti-TNF-α BV605 (BD 
Biosciences).
Transcription factors analysis: 1 million of BAL cells were washed with 3 mL of PBS and 
stained with Aqua Viability dye (LIVE/DEAD Fixable Dead Cell Stain kit, Invitrogen, UK) and 
the surface markers CD3-APC.cy7, CD4–PerCP5.5, CD8–AF700, CD69–BV650, anti-CD25-
PE-TexasRed and CD45-BV711 (Biolegend, San Diego, CA). For permeabilization and 
fixation, Foxp3/Transcription Factor Staining Buffer Set (eBiosciences, San Diego, CA) was 
used as per the manufacturer’s instructions, following intracellular staining with T-bet-APC, 
Gata-3-PE and Foxp3-FITC. All samples were acquired on a LSRII flow cytometer (BD 
Biosciences).
Page 37 of 51  AJRCCM Articles in Press. Published on 18-October-2019 as 10.1164/rccm.201903-0607OC 
 Copyright © 2019 by the American Thoracic Society 
INF-γ, TNF-α and IL-17 producing CD4+ T cells post stimulation with HI-Spn6B:  Cells were 
harvested, stained and analysed as previously described, with minor modifications(5, 9). In 
brief, non-adherent cells were collected from the BAL samples post an adherence step, 
centrifuged at 400g for 5min, resuspended in complete RPMI and seeded in 96-well plates at 
equal concentrations of 600,000 to 1 million cells per condition. Cells were stimulated with 
5μg/ml of HI-Spn6B and incubated for 2 hours at 37oC, following addition of GolgiPlug (BD 
Biosciences) and overnight incubation at 37oC, 5% CO2. A non-stimulated with Spn6B (mock) 
cell condition was included per volunteer.  After 16 hours, the cells were washed with PBS 
and stained with Violet Viability dye (LIVE/DEAD Fixable Dead Cell Stain kit, Invitrogen, UK) 
and anti-CD3-APCH7, TCR-γδ–PECy7 (BD Biosciences, USA), anti-CD4–PerCP5.5, anti-
CD8–AF700, anti-CD69–BV650, anti-CD25-PE.TxsRed, anti-CD103–BV605, anti-CD49a-
APC (Biolegend, San Diego, CA). For the assessment of intracellular cytokine production, 
after permeabilization and fixation, the cells were stained with the following markers: anti-IFN-
γ-PE, anti-IL17A–BV510 and TNF-α–BV711 (BD Biosciences). All samples were acquired on 
a LSRII flow cytometer (BD Biosciences).
AMs gene analysis using Nanostring platform
Nanostring was used as previously described (10). Briefly, AMs were sorted by FACS ARIAIII 
cell sorter and stored in RLT buffer (Qiagen) with 1% 2-mercaptoethanol (Sigma) at -80C until 
RNA extraction. Extraction was performed using the RNEasy micro kit (Qiagen) with on 
column DNA digestion. Extracted RNA was quantified by qPCR targeting B2M gene 
(Bioanalyzer, Agilent).  The single cell immunology v2 kit (Nanostring) was used with 20 pre-
amp cycles for all samples. Hybridized samples were prepared on a Prep Station and scanned 
on a nCounter® MAX (Nanostring). Raw counts were analysed using the R/Bioconductor 
package DESeq2 for internal normalization, which gave lower variance than normalizing to 
included housekeeping genes. DEG were identified using a model matrix correcting for 
repeated individual measurements. Log CPM from raw counts were calculated using the 
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‘edgeR’ package. 2logFold chances were further analysed by the ‘fgsea’ package, through 
BMT pathways gene set enrichment analysis. 
Results 
Methods of spn6B DNA detection in BAL and NPS
Carriage pos. Carriage neg.
Spn6B detected in the BAL by qPCR
9/22 (41%) 0/21 (0%)
Live Spn6B detected in BAL by culturing 
2/16 (12.5%) 0/10 (0%)
Spn6B DNA detected in NP swabs by qPCR
0/12 (0%) 0/10 (0%)
Live Spn6B detected in NP swabs by culturing
0/12 (0%) 0/10 (0%)
Table S1. Methods of Spn6B detection in lung and nose the day of research 
bronchoscopy. Spn6B DNA was detected in 41% of carriage positive volunteers (9 in 22 
carriers) by qPCR targeting a Spn6B specific capsular polysaccharide gene. Spn6B DNA was 
not detected in any (0/21) non-colonised subjects. BAL samples were plated on blood agar 
plate and pneumococcal growth was observed in 12.5% (2/16) Spn-colonised volunteers, 
whereas there was no growth for any the carriage negatives (0/10). Nasopharyngeal (NP) 
swabs were taken prior to the bronchoscopy from 22 participants. SPN6B was not detected in 
any NP sample after culturing or qPCR analysis.  
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a b
Supplementary video 1: Spn6 pneumococci internalised by alveolar macrophages.   
Video images of 3D reconstruction of deconvolved Z-stack confocal images of human alveolar 
macrophages. The samples were stained with anti-CD169 monoclonal antibody (panel A; red) 
or wheat germ agglutinin (panel B; magenta). Spn6 polysaccharide capsule was stained in 
green and nuclei are shown in blue (DAPI).   
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Figure S1: Gating strategy of C3+CD4+ T cells for transcriptions factors – T-bet, GATA-3 and 
FoxP3 - expression for one representative volunteer. 
Page 41 of 51  AJRCCM Articles in Press. Published on 18-October-2019 as 10.1164/rccm.201903-0607OC 
 Copyright © 2019 by the American Thoracic Society 
Figure S2: Gating strategy of cytokine (INF-γ, TNF-α and IL-17A) producing T cells following 
overnight stimulation with HI-Spn6B or not. Gates from one representative volunteer are 
shown.
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Cytokine
Median 
concentration 
Carriage neg.
Median 
concentration 
Carriage pos.
p-value adjusted p-value
IL2 0.17 0.17 9.36E-01 9.36E-01
IL17 0.30 0.30 1.42E-01 6.34E-01
TNFα 0.42 0.42 7.41E-01 9.31E-01
FGF 
Basic 0.65 0.65 1.83E-01 6.34E-01
GM-CSF 0.49 0.96 3.41E-02 4.84E-01
EGF 1.01 1.01 6.19E-01 9.12E-01
IL 10 0.92 1.11 4.43E-01 8.31E-01
IL 1β 1.09 1.09 2.90E-01 7.25E-01
IL 4 1.25 1.24 6.17E-01 9.12E-01
Eotaxin 1.19 1.33 9.14E-01 9.36E-01
RANTES 1.79 1.79 9.03E-01 9.36E-01
IL 5 2.30 2.78 3.61E-01 8.31E-01
IFN-γ 1.89 3.20 4.84E-02 4.84E-01
IFNα 2.96 3.61 4.43E-02 4.84E-01
MIG 2.07 7.37 1.11E-01 6.34E-01
IL 13 4.87 6.03 1.00E-01 6.34E-01
IL 12 8.13 7.07 8.84E-01 9.36E-01
MIP 1α 9.35 9.57 4.29E-01 8.31E-01
MIP 1β 11.00 11.42 5.03E-01 8.87E-01
IL 15 16.56 11.29 2.32E-01 6.34E-01
IL 6 13.49 16.22 2.03E-01 6.34E-01
IL 2R 17.62 22.65 4.06E-01 8.31E-01
IL 7 17.58 25.34 1.77E-01 6.34E-01
IP 10 23.07 29.58 2.12E-01 6.34E-01
G-CSF 33.03 43.81 7.33E-01 9.31E-01
MCP 1 51.34 48.13 8.95E-01 9.36E-01
VEGF 56.40 61.40 6.38E-01 9.12E-01
HGF 79.20 73.13 8.00E-01 9.36E-01
IL 8 61.92 90.55 5.38E-01 8.97E-01
IL 1RA 959.97 775.27 7.45E-01 9.31E-01
Table S2.  Levels of 30 cytokines and chemokines measured the in the BAL fluid of 
carriage negative (n=20) and carriage positive (n=22) volunteers, who underwent 
research bronchoscopy up to 50 days post the pneumococcal inoculation. Levels are 
expressed as pg/ml and are ordered from low to high values. Median per group, p-
values by Mann-Whitney test and p-values corrected by multiple-comparison testing 
(Benjamini-Hochberg) are displayed. 
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Figure S3: Intracellular cytokine staining gating strategy of TNF-a production. AMs post 
treatment with IFN-γ and stimulation with HI-Spn6B.  Gates from one representative volunteer 
are shown. 
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Figure S4: Gating strategy of monocyte analysis for one representative volunteer. 
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pathway LeadingEdge
chemokine cluster (I) 
(M27.0)
("CXCL2", "CXCL11", "CXCL10", "IL8", "CCL13", "CCL18", 
"PPBP", "CCL20")
regulation of antigen 
presentation and 
immune response 
(M5.0)
("HLA-DQA1", "CLEC7A", "LY96", "HLA-DPB1", "CD247", 
"FYN", "TLR1", "LILRB1", "IRAK3", "TLR7", "PTPN22", 
"CD19")
Monocyte surface 
signature (S4)
("FCGR2A", "TLR4", "TNFRSF1B", "LILRB2", "LTBR", "CD36", 
"TNFSF12", "CD163", "MARCO", "PYCARD", "CD4", 
"FCGRT", "PTAFR")
Table S3: List of differentially expressed genes presented in the pathways identified by gene 
set enrichment analysis 
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adjusted 
Gene log2FoldChange p-value
p-value
C1QA -1.73 1.17E-03 4.25E-01
CD14 -1.86 3.95E-03 5.00E-01
CSF1R -1.84 7.82E-03 5.00E-01
IRF4 1.77 8.43E-03 5.00E-01
C1QB -1.66 9.23E-03 5.00E-01
CXCL11 1.96 1.05E-02 5.00E-01
GPI -1.27 1.13E-02 5.00E-01
NT5E 1.38 1.81E-02 5.00E-01
CCND3 -1.45 1.83E-02 5.00E-01
CLEC7A 2.37 2.10E-02 5.00E-01
CEACAM6 1.29 2.16E-02 5.00E-01
LY96 2.19 2.24E-02 5.00E-01
TAPBP -1.34 2.41E-02 5.00E-01
TNFSF4 1.32 2.61E-02 5.00E-01
HLA-
DRB3 -3.36 2.82E-02 5.00E-01
ITGAX -1.83 2.85E-02 5.00E-01
IL13 1.18 2.98E-02 5.00E-01
FCGRT -1.32 3.18E-02 5.00E-01
CMKLR1 -1.55 3.28E-02 5.00E-01
TNFSF13B 1.78 3.37E-02 5.00E-01
CD164 2.01 3.48E-02 5.00E-01
S100A8 -1.46 3.52E-02 5.00E-01
CXCL2 2.08 3.62E-02 5.00E-01
PYCARD -1.02 3.62E-02 5.00E-01
TBX21 1.42 3.67E-02 5.00E-01
TAGAP 1.08 3.72E-02 5.00E-01
KLRC4 1.24 3.78E-02 5.00E-01
CCRL1 1.27 3.85E-02 5.00E-01
GAPDH -1.42 4.05E-02 5.08E-01
IL10RA -1.14 4.48E-02 5.43E-01
TLR8 1.56 4.72E-02 5.45E-01
KIR3DL2 1.25 4.84E-02 5.45E-01
ITGB2 -1.41 4.94E-02 5.45E-01
Table S4. List of differentially expressed genes (DEG with p < 0.05) in sorted AMs on the day 
of the bronchoscopy (36 to 115 days post intranasal inoculation), compared Spn colonised 
(n=5) to non-colonised (n=5) individuals. Log2fold change (carriage positive over carriage 
negative), p-values by Mann-Whitney test and corrected p-values by using Benjamini-
Hochberg procedure are displayed. 
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Gene p value Rho
KLRD1 0.007 0.818
SLAMF1 0.008 0.806
IL13RA1 0.011 0.760
CCL15 0.016 0.758
KIR3DL1 0.018 0.745
KLRAP1 0.018 0.745
IL16 0.021 0.733
PRDM1 0.024 0.721
CCR10 0.028 0.709
LAG3 0.028 0.709
TRAF4 0.028 0.709
IRF8 0.030 0.681
EDNRB 0.035 0.669
KLRK1 0.035 0.669
IL6R 0.035 0.685
NT5E 0.035 0.685
ZAP70 0.035 0.685
DPP4 0.039 0.657
CD7 0.039 0.673
CEACAM6 0.039 0.673
FCER1A 0.039 0.673
LILRA4 0.039 0.673
IL12A 0.042 0.650
BCL2 0.044 0.661
MASP2 0.044 0.661
TBX21 0.044 0.661
TNFRSF9 0.044 0.661
HLA.DOB 0.049 0.648
IRF5 0.049 0.648
LILRA3 0.049 0.648
LILRA5 0.049 0.648
SELL 0.049 0.648
TLR8 0.049 0.648
TNFRSF14 0.049 0.648
Table S5. List of genes for which expression significantly positively correlates with AM 
opsonophagocytic activity. 
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